Biotech Analysts, along with Dr. Dagny Zhu of Hyperspeed LASIK a board-certified ophthalmologist & LASIK surgeon specializing in cornea, cataract, and laser refractive surgery, discuss the commercial opportunity of Tarsus Pharmaceuticals XDEMVY for Demodex Blepharitis on an Analyst/Industry conference call to be held on November 15.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARS:
- Tarsus Pharmaceuticals price target raised to $50 from $42 at H.C. Wainwright
- Tarsus Pharmaceuticals files $300M mixed securities shelf
- Tarsus Pharmaceuticals reports Q3 EPS ($1.28), consensus ($1.40)
- Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
- Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023